&nbsp;

test.png

Jun 2024

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2023

Status: Current
Version: PET 2023-2

Jun 2024

Document

EmotionalandPsychologicalWell-beingforGyngecologicalCancerSurvivors.pdf

Jul 2024

Document

Emotional-and-Psychological-Well-being-Gynecological_FR.pdf

Jul 2024

Drug

epcoritamab

Other Name(s): Epkinly™

Quick Link(s): Drug Monograph, Patient Info Sheet

Oct 2025

Regimen

TARL; TARL(RAMP)

Cancer Type:

Lung,

Small Cell

Intent: Palliative

Drugs Used:

tarlatamab (Compassionate)

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

ENHE

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

Enhertu trastuzumab deruxtecan (Unfunded)

Quick Link(s):

Regimen Monograph

May 2025

Drug

teclistamab

Other Name(s): Tecvayli®

Quick Link(s): Drug Monograph, Patient Info Sheet

Oct 2025

Regimen

ENFO+PEMB

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer

New Drug Funding Program

Enfortumab Vedotin with Pembrolizumab - Previously Untreated Locally Advanced Unresectable or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin,

pembrolizumab

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

ENHE

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab Deruxtecan - Previously Treated Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Enhertu trastuzumab deruxtecan

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Document